HC Wainwright Lowers Emergent Biosolutions (NYSE:EBS) Price Target to $12.00

Emergent Biosolutions (NYSE:EBS) had its price objective dropped by HC Wainwright from $15.00 to $12.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 44.75% from the company’s previous close.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Emergent Biosolutions has an average rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Price Performance

Shares of EBS stock opened at $8.29 on Monday. Emergent Biosolutions has a 52 week low of $4.02 and a 52 week high of $14.06. The stock has a market capitalization of $435.39 million, a PE ratio of 9.87 and a beta of 2.41. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. The stock’s fifty day moving average is $11.29 and its 200-day moving average is $10.41.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.54). The company had revenue of $148.70 million for the quarter, compared to analyst estimates of $217.50 million. Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%. Equities research analysts expect that Emergent Biosolutions will post -0.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $31,000. Ameritas Investment Partners Inc. bought a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at about $35,000. Torren Management LLC bought a new position in Emergent Biosolutions during the 4th quarter worth approximately $37,000. CANADA LIFE ASSURANCE Co bought a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $45,000. Finally, Raymond James Financial Inc. bought a new stake in Emergent Biosolutions in the second quarter valued at approximately $53,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.